Recomendaciones para el uso de metotrexato en pacientes con artritis idiopática juvenil
- I. Calvo
- J. Antón
- Juan Carlos López Robledillo
- Jaime de Inocencio Arocena
- M.L. Gamir
- R. Merino
- L. Lacruz
- J.M. Camacho Alonso
- M. J. Ruá
- Sagrario Bustabad Reyes
- G. Díaz Cordovés-Rego
ISSN: 1695-4033, 1696-4608
Year of publication: 2016
Volume: 84
Issue: 3
Pages: 177-177
Type: Article
More publications in: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )
Abstract
Objectives To develop a consensus document of recommendations for the use of methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA). Material and method A group of eleven experts proposed several clinical questions on the use of MTX in patients with JIA. A systematic review was conducted and the evidence and recommendations for each question were extracted. The results were discussed and validated by the experts in a work session to establish the final recommendations. Results MTX is recommended as the first drug for inducing remission in JIA, and its indication should be made according to the clinical category of the patient. Prior to treatment, it is recommended to perform a complete blood count, including white cells, levels of liver enzymes, serum creatinine, and other analytical parameters according to specific risk factors. Treatment should be initiated with a dose of 10-15mg/m2/week. In cases of uveitis or polyarthritis, an initial dose of 15mg/m2/week should be considered. For a better bioavailability and tolerability, it is preferable to administer MTX parenterally if the dose is ≥15mg/m2/week. It is necessary to periodically perform an analytical monitoring of the patient and to assess possible alterations in liver enzymes to make changes if necessary. Combinations with biological agents may be necessary, as well as the concomitant addition of folic or folinic acid. Conclusions This document describes the main recommendations for the appropriate use of MTX in JIA patients, according to scientific evidence and clinical experience.